CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 56 enrolled
Drug / intervention
Blood lipid monitoring in breast cancer patients during chemotherapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06958783
NCT06958783N/ACompleted

Detection of Changes in the Lipid Profile in Early-Stage Breast Cancer Patients Undergoing Neoadjuvant or Adjuvant Chemotherapy

Cancer center Stefan Kukura Hospital Michalovce·observational·Posted May 6, 2025·Updated May 30, 2025

In Brief

An observational study evaluating Blood lipid monitoring in breast cancer patients during chemotherapy for Breast Neoplasms and 2 related conditions. Completed, enrolled 56 participants across 1 site.

Detailed Summary

Detection of changes in the lipid profile in early-stage breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSlovakia

Timeline

N/ACompletedFinished
202420252026
First PostedMay 6, 2025
Enrollment StartMar 5, 2023
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 1.2 years ago

Interventions

Blood lipid monitoring in breast cancer patients during chemotherapyother

This intervention is distinguished by its prospective design, enrollment of a clearly defined cohort of adult female patients with newly diagnosed early-stage breast cancer (stage IB-IIIB), administration of a uniform chemotherapy regimen (doxorubicin, cyclophosphamide, paclitaxel), and standardized monitoring of fasting lipid profiles at four precisely scheduled timepoints: pre-chemotherapy, pre-paclitaxel, post-paclitaxel, and three months post-chemotherapy completion